hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Research shows it plays a crucial role in wound healing, tissue remodeling, and skin regeneration
Methods Study subjects This study was approved by the Institutional Review Board of the Baylor College of Medicine Biomedical Research and Assurance Information Network (BRAIN) under protocol number H-31612
The IV therapy itself was smooth and efficient
Anti-CD20 therapy depletes activated myelin-specific CD8
their dark under eye circles disappear, they feel more clearminded and energetic, and their wrinkles look less intense